LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

GSK has announced that a pre-filled syringe version of its Shingrix shingles vaccine has been accepted for review by the ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...

This European review of the prefilled syringe follows GSK's receipt of approval from the US Food & Drug Administration on January 8. GSK is also investigating submission of the new presentation to ...

(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...

GSK announced on Friday that the US Food and Drug Administration (FDA) has accepted its regulatory application for a prefilled syringe version of Shingrix, its recombinant zoster vaccine for ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has accepted for review the regulatory application of a prefilled syringe ...

GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix, the Recombinant Zoster Vaccine ...